(+)-VINCRISTINE
EGFR Exon 19 Deletion Mutation
Academic and Community Cancer Research UnitedSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the EGFR Exon 19 Deletion Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Academic and Community Cancer Research United | Phase 2 | B |
Panobinostat Academic and Community Cancer Research United | Phase 2 | B |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →